DAFTAR PUSTAKA

Ahlawat, R., Tiwari, P., & D'Cruz, S. (2017). Direct Cost for Treating Chronic Kidney Disease at an Outpatient Setting of a Tertiary Hospital: Evidence from a Cross-Sectional Study. *Value in Health Regional Issues*, *12*, 36–40. https://doi.org/10.1016/j.vhri.2016.10.003

Alexander, S., Jasuja, S., Gallieni, M., Sahay, M., Rana, D. S., Jha, V., Verma, S., Ramachandran, R., Bhargava, V., Sagar, G., Bahl, A., Mostafi, M., Pisharam, J. K., Tang, S. C. W., Jacob, C., Gunawan, A., Leong, G. B., Thwin, K. T., Agrawal, R. K., … Vachharajani, T. (2021). Impact of National Economy and Policies on End-Stage Kidney Care in South Asia and Southeast Asia. *International Journal of Nephrology*, *2021*. https://doi.org/10.1155/2021/6665901

Aromataris, E., & Pearson, A. (2014). The systematic review: An overview. *American Journal of Nursing*, *114*(3), 53–58. https://doi.org/10.1097/01.NAJ.0000444496.24228.2c

Aromataris, E., & Riitano, D. (2014). Constructing a search strategy and searching for evidence. *American Journal of Nursing*, *114*(5), 49–56. https://doi.org/10.1097/01.NAJ.0000446779.99522.f6

Azalea, M., Andayani, T. M., & Satibi. (2016). Analisis Biaya Pengobatan Penyakit Ginjal Kronis Rawat Inap dengan Hemodialisis di Rumah Sakit. *Jurnal Manajemen Dan Pelayanan Farmasi*, *6*(2), 141–150.

Bharati, J., & Jha, V. (2022). Global Kidney Health Atlas: a spotlight on the Asia-Pacific sector. *Kidney Research and Clinical Practice*, *41*(1), 22–30. https://doi.org/10.23876/j.krcp.21.236

Bhowmik, D., Song, X., Intorcia, M., Kent, S. T., & Shi, N. (2018). Healthcare Resource Use and Costs Associated with Chronic Kidney Disease in US Private Insurance Patients with Multiple Myeloma. *Journal of Oncology Pharmacy Practice*, *25*(4), 855–864. https://doi.org/10.1177/1078155218766408

Burr, J., & Vale, L. (2015). *47 - Medical Management of Glaucoma: Cost-Effectiveness* (T. M. Shaarawy, M. B. Sherwood, R. A. Hitchings, & J. G. B. T.-G. (Second E. Crowston (eds.); pp. 509–513). W.B. Saunders. https://doi.org/https://doi.org/10.1016/B978-0-7020-5193-7.00047-9

Catić, T. (2015). Cost of Illness Studies and Its Importance in Bosnia and Herzegovina Environment. *Pharmacia*, *18*(2), 195–200. https://www.researchgate.net/publication/299483236

Chisholm-Burns, M. A., Schwinghammer, T. L., Wells, B. G., Malone, P. M., Kolesar, J. M., & DiPiro, J. T. (2016). *Pharmacotherapy Principles & Practice* (Fourth, Vol. 148). McGraw-Hill Education.

Cloutier, M., Manceur, A. M., Guerin, A., Aigbogun, M. S., Oberdhan, D., & Gauthier-Loiselle, M. (2020). The Societal Economic Burden of Autosomal Dominant Polycystic Kidney Disease in the United States. *BMC Health Services Research*, *20*(1), 126. https://doi.org/10.1186/s12913-020-4974-4

Coentrão, L. A., Araújo, C. S., Ribeiro, C. A., Dias, C. C., & Pestana, M. J. (2013). Cost Analysis of Hemodialysis and Peritoneal Dialysis Access in Incident

Dialysis Patients. *Peritoneal Dialysis International*, *33*(6), 662–670. https://doi.org/10.3747/pdi.2011.00309

Costa, N., Derumeaux, H., Rapp, T., Garnault, V., Ferlicoq, L., Gillette, S., Andrieu, S., Vellas, B., Lamure, M., Grand, A., & Molinier, L. (2012). Methodological considerations in cost of illness studies on Alzheimer disease. *Health Economics Review*, *2*(1), 1–12. https://doi.org/10.1186/2191-1991-2-18

Da Silva, G. B., De Oliveira, J. G. R., De Oliveira, M. R. B., De Souza Vieira, L. J. E., & Dias, E. R. (2018). Global costs attributed to chronic kidney disease: A systematic review. *Revista Da Associacao Medica Brasileira*, *64*(12), 1108–1116. https://doi.org/10.1590/1806-9282.64.12.1108

de Abreu, M. M., Walker, D. R., Sesso, R. C., & Ferraz, M. B. (2013). A Cost Evaluation of Peritoneal Dialysis and Hemodialysis in the Treatment of End-Stage Renal Disease in São Paulo, Brazil. *Peritoneal Dialysis International*, *33*(3), 304–315. https://doi.org/10.3747/pdi.2011.00138

de Vries, E. F., Los, J., de Wit, G. A., & Hakkaart - van Roijen, L. (2021). Patient, family and productivity costs of end-stage renal disease in the Netherlands; exposing non-healthcare related costs. *BMC Nephrology*, *22*(1), 1–9. https://doi.org/10.1186/s12882-021-02548-y

DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2017). *Pharmacotherapy: A Pathophysiologic Approach* (Tenth). McGraw-Hill Education.

Elshahat, S., Cockwell, P., Maxwell, A. P., Griffin, M., O'Brien, T., & O'Neill, C. (2020). The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. *PLoS ONE*, *15*(3), 1–19. https://doi.org/10.1371/journal.pone.0230512

Ene-Iordache, B., Perico, N., Bikbov, B., Carminati, S., Remuzzi, A., Perna, A., Islam, N., Bravo, R. F., Aleckovic-Halilovic, M., Zou, H., Zhang, L., Gouda, Z., Tchokhonelidze, I., Abraham, G., Mahdavi-Mazdeh, M., Gallieni, M., Codreanu, I., Togtokh, A., Sharma, S. K., … Remuzzi, G. (2016). Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study. *The Lancet Global Health*, *4*(5), e307–e319. https://doi.org/10.1016/S2214-109X(16)00071-1

Eriksson, D., Karlsson, L., Eklund, O., Dieperink, H., Honkanen, E., Melin, J., Selvig, K., & Lundberg, J. (2017). Real-World Costs of Autosomal Dominant Polycystic Kidney Disease in the Nordics. *BMC Health Services Research*, *17*(560), 1–9. https://doi.org/10.1186/s12913-017-2513-8

Eriksson, J. K., Neovius, M., Jacobson, S. H., Elinder, C. G., & Hylander, B. (2016). Healthcare Costs in Chronic Kidney Disease and Renal Replacement Therapy: A Population-based Cohort Study in Sweden. *BMJ Open*, *6*(10), 1–9. https://doi.org/10.1136/bmjopen-2016-012062

Fathima, S., Mateti, U. V., Philip, M. L., & Kamath, J. (2018). Pharmacoeconomic Evaluation of Hemodialysis Patients: A study of Cost of Illness. *Journal of Integrative Nephrology and Andrology*, *5*(2), 54–59. https://doi.org/10.4103/jina.jina_4_18

Fauziah, Wahyono, D., & Budiarti, L. E. (2015). Cost of Illness Dari Chronic

Kidney Disease dengan Tindakan Hemodialisis. *Jurnal Manajemen Dan Pelayanan Farmasi*, *5*(3), 149–158.

Folkerts, K., Petruski-Ivleva, N., Kelly, A., Fried, L., Blankenburg, M., Gay, A., & Kovesdy, C. P. (2020). Annual Health Care Resource Utilization and Cost Among Type 2 Diabetes Patients with Newly Recognized Chronic Kidney Disease within a Large U.S. Administrative Claims database. *Journal of Managed Care & Specialty Pharmacy*, *26*(12), 1506–1516. https://doi.org/10.18553/jmcp.2020.26.12.1506

Freeman, C., Giles, L., Field, P., Sörstadius, E., & van Haalen, H. (2019). Humanistic burden and economic impact of chronic kidney disease: a systematic literature review. *F1000Research*, *8*, 2142. https://doi.org/10.12688/f1000research.21374.1

Gagnon-Sanschagrin, P., Liang, Y., Sanon, M., Oberdhan, D., Guérin, A., & Cloutier, M. (2021). Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage. *Journal of Medical Economics*, *24*(1), 193–201. https://doi.org/10.1080/13696998.2021.1877146

Gandjour, A., Armsen, W., Wehmeyer, W., Multmeier, J., & Tschulena, U. (2020). Costs of Patients with Chronic Kidney Disease in Germany. *PloS One*, *15*(4), 1–14. https://doi.org/10.1371/journal.pone.0231375

Goncalves, G. M. R., & Silva, E. N. da. (2018). Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System. *PloS One*, *13*(10), e0203992. https://doi.org/10.1371/journal.pone.0203992

Harris, J. D., Quatman, C. E., Manring, M. M., Siston, R. A., & Flanigan, D. C. (2014). How to write a systematic review. *American Journal of Sports Medicine*, *42*(11), 2761–2768. https://doi.org/10.1177/0363546513497567

Hauben, E. I., & Hogendoorn, P. C. W. (2015). *Chapter 1 - Epidemiology of primary bone tumors and economical aspects of bone metastases* (D. B. T.-B. C. (Second E. Heymann (ed.); pp. 5–10). Academic Press. https://doi.org/https://doi.org/10.1016/B978-0-12-416721-6.00001-7

Honeycutt, A. A., Segel, J. E., Zhuo, X., Hoerger, T. J., Imai, K., & Williams, D. (2013). Medical Costs of CKD in the Medicare Population. *Journal of the American Society of Nephrology*, *24*(9), 1478–1483. https://doi.org/10.1681/ASN.2012040392

Jeet, G., Masaki, E., Vassall, A., & Prinja, S. (2021). Costing of Essential Health Service Packages: A Systematic Review of Methods From Developing Economies. *Value in Health*, *24*(11), 1700–1713. https://doi.org/10.1016/j.jval.2021.05.021

Jo, C. (2014). Cost-of-illness studies: concepts, scopes, and methods. *Clinical and Molecular Hepatology*, *20*(4), 327–337. https://doi.org/10.3350/cmh.2014.20.4.327

Jommi, C., Armeni, P., Battista, M., di Procolo, P., Conte, G., Ronco, C., Cozzolino, M., Costanzo, A. M., di Luzio Paparatti, U., Concas, G., & Remuzzi, G. (2018). The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. *PharmacoEconomics*

- *Open*, *2*(4), 459–467. https://doi.org/10.1007/s41669-017-0062-z

Karopadi, A. N., Mason, G., Rettore, E., & Ronco, C. (2013). Cost of peritoneal dialysis and haemodialysis across the world. *Nephrology Dialysis Transplantation*, *28*(10), 2553–2569. https://doi.org/10.1093/ndt/gft214

Kassa, D. A., Mekonnen, S., Kebede, A., & Haile, T. G. (2020). Cost of Hemodialysis Treatment and Associated Factors Among End-Stage Renal Disease Patients at the Tertiary Hospitals of Addis Ababa City and Amhara Region, Ethiopia. *ClinicoEconomics and Outcomes Research*, *12*, 399–409. https://doi.org/10.2147/CEOR.S256947

KDIGO. (2012). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International Supplements*, *3*(1), 150. https://doi.org/https://doi.org/10.1038/kisup.2012.72.

Kelly, P., Rao, D. S. P., Sinha, D. K., & Yiftach, M. (2021). *A Guide to the Integration of Consumer Price Index (CPI) and International Comparison Program (ICP) Production Activities*.

Kent, S., Schlackow, I., Lozano-Kühne, J., Reith, C., Emberson, J., Haynes, R., Gray, A., Cass, A., Baigent, C., Landray, M. J., Herrington, W., & Mihaylova, B. (2015). What is the Impact of Chronic Kidney Disease Stage and Cardiovascular Disease on the Annual Cost of Hospital Care in Moderate-to-severe Kidney Disease? *BMC Nephrology*, *16*(65), 1–8. https://doi.org/10.1186/s12882-015-0054-0

Khan, A., Jan, F. A., & Rashid, H. (2021). Economic Burden of End Stage Renal Disease: A Study from India. *Scholars Journal of Economics, Business and Management*, *8*(February), 1–3. https://doi.org/10.36347/sjebm.2021.v08i01.00X

Kim, S.-H., Jo, M.-W., Go, D.-S., Ryu, D.-R., & Park, J. (2017). Economic Burden of Chronic Kidney Disease in Korea Using National Sample Cohort. *Journal of Nephrology*, *30*(6), 787–793. https://doi.org/10.1007/s40620-017-0380-3

Klomjit, N., Kattah, A. G., & Cheungpasitporn, W. (2021). The Cost-effectiveness of Peritoneal Dialysis Is Superior to Hemodialysis: Updated Evidence From a More Precise Model. *Kidney Medicine*, *3*(1), 15–17. https://doi.org/10.1016/j.xkme.2020.12.003

Knight, T., Schaefer, C., Krasa, H., Oberdhan, D., Chapman, A., & Perrone, R. D. (2015). Medical Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease in the USA: A Retrospective Matched Cohort Analysis of Private Insurer Data. *ClinicoEconomics and Outcomes Research*, *7*, 123–132. https://doi.org/10.2147/CEOR.S75523

Kristina, S. A., Endarti, D., Andayani, T. M., & Aditama, H. (2021). Cost of Illness of Hemodialysis in Indonesia: A Survey from Eight Hospitals in Indonesia. *International Journal of Pharmaceutical Research*, *13*(01). https://doi.org/10.31838/ijpr/2021.13.01.375

Larg, A., & Moss, J. R. (2011). Cost-of-Illness Studies: A Guide to Critical Evaluation. *Pharmacoeconomics*, *29*(8), 653–671. https://doi.org/10.2165/11588380-000000000-00000

Mandrik, O. (Lena), Severens, J. L. (Hans., Bardach, A., Ghabri, S., Hamel, C., Mathes, T., Vale, L., Wisløff, T., & Goldhaber-Fiebert, J. D. (2021). Critical

Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report. *Value in Health*, *24*(4), 463–472. https://doi.org/10.1016/j.jval.2021.01.002

Manjula, M., Deepak, P., Suresh, R. M., & Raghu, N. (2021). Cost Analysis of Haemodialysis Patients in Government Tertiary Care Centre – A Pharmacoeconomic Study. *Pharmacology and Clinical Pharmacy Research*, *6*(2), 94. https://doi.org/10.15416/pcpr.v6i2.32069

Manns, B., Hemmelgarn, B., Tonelli, M., Au, F., So, H., Weaver, R., Quinn, A. E., & Klarenbach, S. (2019). The Cost of Care for People With Chronic Kidney Disease. *Canadian Journal of Kidney Health and Disease*, *6*, 1–11. https://doi.org/10.1177/2054358119835521

Nabila, A. (2015). Analisis Biaya Satuan dan Kualitas Hidup Penderita Gagal Ginjal Kronik yang Menggunakan Tindakan Hemodialisis di Rumah Sakit Tebet Tahun 2015. *Jurnal Administrasi Rumah Sakit*, *1*(3), 124–134.

Naoum, P., Topkaroglou, I., Kitsonis, D., Skroumpelos, A., Athanasakis, K., Iatrou, C., Boletis, J., & Kyriopoulos, J. (2016). Cost Calculations during "dire straits": A Cost-of-Illness Analysis of Regular Hemodialysis for End-Stage Renal Disease in Greece. *International Journal of Artificial Organs*, *39*(2), 87–89. https://doi.org/10.5301/ijao.5000477

OECD. (2022). *Conversion rates - Purchasing power parities (PPP) - OECD Data*. https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *International Journal of Surgery*, *88*, 1–11. https://doi.org/10.1016/j.ijsu.2021.105906

Rascati, K. L. (2014). *Essentials of Pharmacoeconomics* (Second Edi). Lippincott Williams & Wilkins.

Rizk, R., Hiligsmann, M., Karavetian, M., Salameh, P., & Evers, S. M. A. A. (2016). A societal cost-of-illness study of hemodialysis in Lebanon. *Journal of Medical Economics*, *19*(12), 1157–1166. https://doi.org/10.1080/13696998.2016.1207653

Roggeri, A., Roggeri, D. P., Zocchetti, C., Bersani, M., & Conte, F. (2017). Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. *Journal of Nephrology*, *30*(2), 263–269. https://doi.org/10.1007/s40620-016-0291-8

Rohenti, I. R., Rahmadaniati, H. U., & Sarnianto, P. (2019). Analisis Biaya Medis Langsung Pasien Hemodialisa di Rumah Sakit X Wilayah Bekasi. *PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia)*, *16*(2), 386–395. https://doi.org/10.30595/pharmacy.v16i2.5731

Saputra, W. C., W.S, S. F. ., Advistasari, Y. D., & Munisih, S. (2020). Cost Of Illness Perawatan Pasien Gagal Ginjal Kronik di Instalasi Rawat Inap Rsi Sultan Agung Semarang. *Jurnal Kesehatan Masyarakat*, *19*(2), 441–447.

http://publikasi.dinus.ac.id/index.php/visikes/article/view/4196

Satyavani, K., Kothandan, H., Jayaraman, M., & Viswanathan, V. (2014). Direct Costs Associated with Chronic Kidney Disease among Type 2 Diabetic Patients in India. *Indian Journal of Nephrology*, *24*(3), 141–147. https://doi.org/10.4103/0971-4065.132000

Shah, K. K., Murtagh, F. E. M., McGeechan, K., Crail, S. M., Burns, A., & Morton, R. L. (2020). Quality of life among caregivers of people with end-stage kidney disease managed with dialysis or comprehensive conservative care. *BMC Nephrology*, *21*(1), 1–8. https://doi.org/10.1186/s12882-020-01830-9

Spinowitz, B., Pecoits-Filho, R., Winkelmayer, W. C., Pergola, P. E., Rochette, S., Thompson-Leduc, P., Lefebvre, P., Shafai, G., Bozas, A., Sanon, M., & Krasa, H. B. (2019). Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. *Journal of Medical Economics*, *22*(6), 593–604. https://doi.org/10.1080/13696998.2019.1588738

Supradono, F., Sarnianto, P., Ramadaniati, H. U., & Hidayat, M. A. (2021). Analisis Profil Pengobatan, Biaya Medis Langsung dan Kualitas Hidup pada Pasien Hemodialisis di Rumah Sakit Bhakti Kartini Kota Bekasi. *Nusantara: Jurnal Ilmu Pengetahuan Sosial*, *8*(8), 2493–2503. https://doi.org/10.31604/jips.v8i8.2021.2493-2503

Tandah, M. R., Ihwan, Diana, K., Zulfiah, & Ambianti, N. (2019). Analisis Biaya Pengobatan Penyakit Ginjal Kronik Rawat Inap dengan Hemodialisis di Rumah Sakit Umum Daerah Undata Palu. *LINK*, *15*(2), 1–7. https://doi.org/10.31983/link.v15i2.5222

Tataradze, A., Managadze, G., Beglarashvili, L., Kipshidze, N., Managadze, L., & Chkhotua, A. (2016). Comparative Costs of Different Renal Replacement Therapies in Lower Middle Income Countries on the Example of Georgia. *International Journal of Clinical Medicine*, *07*(07), 437–444. https://doi.org/10.4236/ijcm.2016.77046

Tekin, R. N., & Şahin, B. (2021). Comparison of Top down and Bottom up Cost Approaches in Colon and Rectal Cancer Treatment. *Health*, *13*(02), 90–109. https://doi.org/10.4236/health.2021.132009

Tod, D., Booth, A., & Smith, B. (2022). Critical appraisal. *International Review of Sport and Exercise Psychology*, *15*(1), 52–72. https://doi.org/10.1080/1750984X.2021.1952471

Turchetti, G., Bellelli, S., Amato, M., Bianchi, S., Conti, P., Cupisti, A., Panichi, V., Rosati, A., Pizzarelli, F., Casani, A., Rosso, G., Capitanini, A., Del Corso, C., Aterini, S., Bozzoli, L., Grazi, G., Guzzo, D., Paparatto, P., Baronti, A., … Scatena, A. (2017). The Social Cost of Chronic Kidney Disease in Italy. *European Journal of Health Economics*, *18*(7), 847–858. https://doi.org/10.1007/s10198-016-0830-1

Villarreal-Ríos, E., Cárdenas-Maldonado, C., Vargas-Daza, E. R., Galicia-Rodríguez, L., Martínez-González, L., & Baca-Baca, R. (2014). Institutional and Familial Cost of Patients in Continuous Ambulatory Peritoneal Dialysis. *Revista Da Associacao Medica Brasileira*, *60*(4), 335–341. https://doi.org/10.1590/1806-9282.60.04.012

Wang, V., Vilme, H., Maciejewski, M. L., & Boulware, L. E. (2016). The Economic

Burden of Chronic Kidney Disease and End-Stage Renal Disease. *Seminars in Nephrology*, *36*(4), 319–330. https://doi.org/10.1016/j.semnephrol.2016.05.008

Wang, X., & Cheng, Z. (2020). Cross-Sectional Studies: Strengths, Weaknesses, and Recommendations. *Chest*, *158*(1), S65–S71. https://doi.org/10.1016/j.chest.2020.03.012

Wells, B. G., DiPiro, J. T., Schwinghammer, T. L., & DiPiro, C. V. (2015). *Pharmacotherapy Handbook* (Ninth). McGraw-Hill Education.

Wyld, M. L. R., Lee, C. M. Y., Zhuo, X., White, S., Shaw, J. E., Morton, R. L., Colagiuri, S., & Chadban, S. J. (2015). Cost to Government and Society of Chronic Kidney Disease Stage 1-5: A National Cohort Study. *Internal Medicine Journal*, *45*(7), 741–747. https://doi.org/10.1111/imj.12797

Yousif, A. O., Idris, A. K. M., Awad, M. M., & El-Samani, E. Z. (2020). Out-of-pocket Payments by End-Stage Kidney Disease Patients on Regular Hemodialysis: Cost of Illness Analysis, Experience from Sudan. *Hemodialysis International*, *25*(1), 123–130. https://doi.org/10.1111/hdi.12895

Zhang, H., Zhang, C., Zhu, S., Zhu, F., & Wen, Y. (2019). Costs of Hospitalization for Chronic Kidney Disease in Guangzhou, China. *Public Administration and Policy*, *22*(2), 138–151. https://doi.org/10.1108/PAP-09-2019-0018